Trilogy Capital’s Halozyme HALO Stock Holding History

Trilogy Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.86M	Buy	+16,807	New	+$1.62M	0.07%	163

Other funds holding HALO

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Trilogy Capital's HALO Position: Q3 2026 in Review

Trilogy Capital opened a new position in Halozyme (HALO) in Q3 2026: 16,807 shares worth $1.86M. The stake represents 0.07% of the portfolio and ranks #163 among its holdings.

161 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

Trilogy Capital held 16,807 shares of Halozyme worth $1.86M as of Q3 2026.
Halozyme was a new Trilogy Capital position in Q3 2026.
Halozyme made up 0.07% of Trilogy Capital's portfolio in Q3 2026, its #163 holding.
161 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Trilogy Capital's 13F filing for Q3 2026, filed 20 Oct 2026.